Coronavirus (COVID-19) Statement

We continue to closely monitor the situation surrounding the COVID-19 pandemic and are following the published recommendations of the CDC and the American Academy of Ophthalmology. We will continue to see our patients and treat any urgent/emergent needs.

With all of our offices open, the following protocols are in place:

1) We have greatly expanded measures to disinfect our office including cleaning between each patient appointment.

2) To limit any potential exposure, we ask you NOT to bring any non-essential person(s) with you to the appointment.

3) If someone must accompany you to your appointment, we ask that they do not enter the office, if at all possible.

4) If you have an upcoming appointment and identify with the following statements, please do not come directly to the office, but instead call us:

• Fever greater than 100.4

• Respiratory symptoms or difficulty breathing

• Exposed to someone with COVID-19 in the past 14 days

• Placed in self/hospital quarantine by medical doctor

 Your health and that of our staff is our guiding priority and we continue to update our protocol to ensure safety for everyone. If you have questions regarding these evolving protocols, please contact our office.

Dr. Cooper CURRICULUM VITAE

Blake Anthony Cooper, M.D.
 

WORK HISTORY

2003 - PRESENT

  • Retina Associates, LLC
    Santa Fe Medical Building
    9301 West 74th Street
    Suite 210
    Shawnee Mission, KS 66204
  • Retina Associates, LLC
    6201 College Boulevard
    Suite 200
    Overland Park, KS 66211
  • Retina Associates, LLC
    4100 North Mulberry Drive
    Suite 100
    Kansas City, MO 64116
  • Retina Associates, LLC
    6001 SW 6th Avenue
    Suite 300
    Topeka, KS 66615
  • Retina Associates, LLC
    3700 W 10th Street
    Suite 101
    Sedalia, MO 65301
  • Retina Associates, LLC
    100 NE Missouri Road
    Suite 203
    Lee's Summit, MO 64086

EDUCATION

  • Current Grad Program 06/2019 - 05/2021
    Masters in Public Health in Epidemiology
    Harvard T.H. Chan School of Public Health
  • Fellowship Ophthalmology/Retina 2001 - 2003
    Barnes Retina Institute/Washington University Medical Center
    St. Louis, MO
  • Resident in Ophthalmology and Visual Sciences 1998 - 2001
    Barnes-Jewish Hospital/Washington University Medical Center
    St. Louis, MO
  • Transitional Medicine, Louis A. Weiss Memorial Hospital 1997 - 1998
    University of Chicago
    Chicago, IL
  • M.D., Finch University of Health Sciences 1993 - 1997
    The Chicago Medical School
    North Chicago, IL
  • B.A., Biology and Chemistry 1988 - 1992
    Knox College
    Galesburg, IL

CERTIFICATIONS

  • American Board of Ophthalmology
  • American College of Surgeons

PROFESSIONAL SOCIETIES AND ORGANIZATIONS

  • Alpha Omega Alpha Honor Medical Society
  • American Academy of Ophthalmology
  • American Association of Clinical Endocrinologists 
  • American Association of Diabetes Educators
  • American Diabetes Association
  • American Society of Ophthalmic Registered Nurses
  • American Society of Retina Specialists
  • Association for Research in Vision and Ophthalmology
  • Diabetic Retinopathy Clinical Research Network
  • Fellow of American College of Surgeons
  • Juvenile Diabetes Research Foundation - Kansas City Chapter Board President 2019
  • Kansas City Diabetes Consortium
  • Kansas City Ophthalmology Journal Club
  • Kansas City Society of Ophthalmology and Otolaryngology - Board President 2019
  • Kansas Society of Eye Physicians and Surgeons
  • Kansas University Department of Ophthalmology - Volunteer Faculty Appointment
  • Midwest Ocular Angiography Conferences
  • Missouri Society of Eye Physicians and Surgeons - Past Board Member
  • Missouri State Medical Association
  • Ocular Imaging Conferences
  • St. Louis Ophthalmology Society
  • Taking Control of Your Diabetes
  • Washington University Department of Ophthalmology - Volunteer Faculty Appointment
  • Western Association for Vitreoretinal Education

PUBLICATIONS AND POSTER PRESENTATIONS

  • Gardner TW, Wyckoff JA, Cooper BA, et al.  Prevention and Management of Diabetes-Related Eye Disease, American Diabetes Association, Arlington, VA 2019.
  • Cooper BA et al.  Smartphone and Medical App Use in a Population Receiving Treatment for Diabetic Retinopathy, Research Poster Presentation, American Association of Diabetes Educators Annual Meeting, August 2018.
  • Cooper, BA et al.  Enhancing Access to Diabetes Self-Management Education in an Ophthalmology Practice, Research poster presentation, American Association of Diabetes Educators Annual Meeting, August 2018.
  • Cooper AG, Cooper BA.  The Burden and Benefits of Teenage Life With Type 1 Diabetes, Kansas City, Medicine: The Journal of the Kansas City Medical Society, Cover Article Winter 2017.
  • Cooper, AG, Cooper BA.  The Burden and Benefits of Teenage Life With Type 1 Diabetes, Missouri Medicine: The Journal of the Missouri Medical Association, September/October 2016 issue.
  • Cooper, AG, Magwire M, Cooper BA.  Knowledge Base of a Typical Diabetic Patient Seeking Care in a Vitreoretinal Surgeons Office, Research Paper and Oral Presentation, American Association of Diabetes Educators Annual Meeting, August 2016.
  • Cooper, AG, Jones A, Jones J, Cooper BA.  The Effects of Stress on Glycemic Control in Type 1 Diabetic Compared to Age-Matched Control Group, Research Paper and Oral Presentation, American Association of Diabetes Educators Annual Meeting, August 2016.
  • Cooper, AG, Jones J, Jones A, Cooper BA. Comparative Use of Smartwatch With Continuous Glucose Monitoring During Alpine Skiing, Research Poster Presentation, American Association of Diabetes Educators Annual Meeting, August 2016.Rajagopal, R, Shah GK, Flinder KJ, Altaweel M, Eliott D, Wee R, Cooper BA, Walia H, Smith BT, Joseph DP.  Bevacizumab versus Ranibizumab in the Treatment of Macular Edema Due to Retinal Vein Occlusion: 6-Month Results of the CRAVE Study, Ophthalmic Surgical Lasers & Imaging Retina 2015 Sept; 46(8):844-50.
  • Cooper, BA, Jones J, Jones A, Cooper A.  The Effect of Altitude and Exercise on Blood Sugar in Type 1 Diabetic Compared With Non-Diabetic Age-Matched Peers, Diabetes: A Journal of the American Diabetes Association, June 2015; Volume 64;Suppl. 1:2511-PO.
  • Ramaiya KJ, Blinder KJ, Ciulla T, Cooper BA, Shah GK. Ranibizumab versus Photodynamic Therapy for Presumed Ocular Histoplasmosis Syndrome, Ophthalmic Surgical Lasers & Imaging Retina 2013 Jan-Feb;441):17-21.
  • Cooper BA, Thomas MA. Surgical Management of CNV Associated With CSRAmerican Journal of Ophthalmology 2000;130:187-191.
  • Cooper BA, Thomas MA, Holekamp NM. Open Retinotomies after Subretinal Surgery, American Journal of Ophthalmology 2000;130:838-839
  • Holekamp NM, Cooper BA. Prophylaxis and Treatment of Post-Surgical Cystoid Macular Edema, Comprehensive Ophthalmology Update, Vol. 1, NO. 4 July – August 2000.
  • Cooper BA, Shah GK. Morning Rounds. Oetting TA (ed). Sometimes a Bark is Worse Than a Bite - Morning Rounds, EyeNet 2000, 4:3:45-46.
  • Cooper BA, Bohigian G, Holekamp NMs. Endophthalmitis after Cataract Surgery: Scleral Tunnel vs Clear Corneal Wounds A Case – Control Study, American Journal of Ophthalmology 2003; 136:300-305.
  • Cooper BA, Shah GK, et al. Outcome of Macular Hole Surgery in Diabetic Patients. Submitted to Ophthalmology. Journal of Retina and Vitreous Diseases 2004;Vol.24;Issue 3:pp 360-362
  • Virata SR, Cooper BA, et al. Retinal Detachments in Fellow Eyes of Patients with Pseudophakic Retinal Detachments, 2004
  • Cooper BA, Grand MG, Shah GK. Photo Essay. Purtscher’s-Like Retinopathy Associated With Systemic Lupus Erthematosus, Ophthalmic Surgery Lasers & Imaging Retina 2004;Sep-Oct; 35(5);438-439.
  • Virata SR, Cooper BA, Busquets MA, Blinder KJ, Grand MG, Holekamp NM, Joseph DP, Merideth TA, Thomas MA, Shah GK.  Retinal Detachments in Fellow Eyes of Patients With Pseudophakic Retinal Detachments, [ARVO Abstract] Invest Ophthalmology Vis Sci 41(4): S664.  Abstract 3528
  • Rao PK, Almony A, Shah GK, Cooper BA, Smith ME. Histologic and Immunohistochemical Features of a Vitreous Cyst, Retinal Cases & Brief Reports 2004;3(1):60-61.
  • Cooper BA, Blinder KJ, Shah GK, Foster W, Leibole M. Femtosecond Laser-Induced Premacular Hemorrhage, Retina 24(5): 812-14, 2004.
  • Cooper BA, Shah GK, Sheidow TG, Blinder KJ, Grand MG. Outcome of Macular Hole Surgery in Diabetic Patients with Nonproliferative Retinopathy, Retina 24(3):360-2, 2004.
  • Cooper BA, Shah GK, Grand MG, Bakal J, Sharma S. Visual Outcomes and Complications Following Multiple Vitrectomies for Diabetic Vitreous Hemorrhage, Retina 24(1):19-22, 2004.
  • Cooper BA, Blinder KJ, Shah GK, Boniuk I. Intruding Scleral Sutures Twelve Years After Primary Repair, Archives of Ophthalmology 122:1238, 2004.
  • Shah GK, Cooper BA, Grand MG, Hart WM. Acute Macular Neuroretinopathy and Associated Disc Swelling and Blind Spot Enlargement – Case Report Canadian Journal of Ophthalmology 38(7):602-04, 2003.
  • Rao PK, Shah GK, Cooper B, Smith M. Histologic and Ultrastructural Features of a Vitreous Cyst, Poster presentation. 21st Annual Meeting American Society of Retina Specialists, Aug. 16-20, 2003.
  • Cooper BA, Shah GK, Rao PK, Smith M. Vitreous Cyst, Verhoeff/Zimmerman Society Meeting. March 2003.
  • Shah GK, Cooper B, Grand MG, Sharma S. Visual Outcomes and Complications Following Multiple Vitrectomies for Diabetic Vitreous Hemorrhage, Poster 03-15. Retina/Vitreous Combined Meeting Sept./Oct. 2002.
  • Cooper BA, Sheidow TG, Grand MG, Sharma S, Shah GK: Outcomes of Macular Hole Surgery in Diabetic Patients, Poster 305. AAO Annual Meeting. November 2001.
  • Virata SR, Shah GK, Cooper BA, Busquets MA, Blinder KJ, Grand MG, Holekamp NM, Joseph DP, Meredith TA, Thomas MA, Sharma S. Retinal Detachments in Fellow Eyes of Patients with Pseudophakic Retinal Detachments, Poster, AAO Annual Meeting, October 24, 2000, Dallas, Texas.
  • Virata SR, Cooper BA, Busquets MA, Blinder KJ, Grand MG, Holekamp NM, Joseph DP, Meredith TA, Thomas MA, Shah GK. Retinal Detachments in Fellow Eyes of Patients with Pseudophakic Retinal Detachments [ARVO Abstract]. Invest Ophthalmology Vis Sci 41(4): S664. Abstract 3528.

LOCAL TALKS, INVITED LECTURES AND PRESENTATIONS

  • The Changing World of Diabetes Management; KC Eye Grand Rounds; October 2019.
  • The Changing World of Diabetes Management; Table Rock Regional Round-Up Annual Meeting; September 2019.
  • Diabetes-Related Retinopathy Update; UMKC Endocrinology Fellowship Invited Lecture; August 2019.
  • The Changing World of Diabetes Management; Moyes Eye Center Grand Rounds; May 2019.
  • Diabetes-Related Retinopathy Update; AACE Annual Meeting; April 2019.
  • Diagnosis and Treatment of Diabetic Retinopathy; Novo Nordisk Global Diabetes Summit, Barcelona, Spain; November 2018.
  • Diagnosis and Treatment of Diabetes-Related Retinopathy; Ophthalmic Anesthesia Society Annual Meeting; September 2018.
  • Newer Diabetic Medications: What Does it Mean for Diabetic Retinopathy/Update of Diabetic Retinopathy: American Society of Ophthalmic Registered Nurses Meeting, Chicago, IL; September 2018.
  • Diagnosis and Treatment of Diabetes-Related Retinopathy; AADE Annual Meeting; August 2018.
  • Diagnosis and Treatment of Diabetes-Related Retinopathy; AACE Heartland Chapter Meeting; August 2018.
  • Diabetes-Related Eye Disease: Bridging the Gap in Care; American Association of Diabetes Educators Annual Meeting, Baltimore, MD; August 2018.
  • Diabetes and Treatment of Diabetic Retinopathy; American Association of Clinical Endocrinologists, Tulsa, OK; August 2018.
  • Case Report of Idiopathic Retinal Vasculitis-Aneurysms-Neuroretinitis Syndrome; Midwest Ocular Angiography Conference, Chiangmai, Thailand; June 2018.
  • Diagnosis and Treatment of Diabetic Retinopathy; Novo Nordisk Global Diabetes Summit, Panama City, Panama; March 2018.
  • Diagnosis and Treatment of Diabetic Retinopathy; Novo Nordisk Semaglutide Training and 2017 Fall Field Medical Affairs Meeting, Atlanta, GA; October 2017.
  • AADE7 Self Care Behaviors and a Retinal Practice; Western Association for Vitreoretinal Education Annual Meeting, Maui, HI; July 2017.
  • Diabetic Retinopathy Update; Taking Control of Your Diabetes Conference and Health Fair; Kansas City; June 2017.
  • Retina 2025 -- Retinal Practice in 10 Years; KCSO&O Annual Meeting; January 2016.
  • Grand MG, Shah GK, Cooper BA, Rosenblatt B. Visual Outcomes After Multiple Vitrectomies, The Retina Debates 2003, AAO Subspecialty Day; November 14-15, 2003.

ADVISORY BOARDS

  • Regeneron Advisory Board

RESEARCH

  • Alcon: C-01-99, Sub-Investigator, Posterior Juxtascleral Injection of Anecortave Acetate versus Sham for Inhibition of CNV in Non-Exudative AMD, 08/2003 – 8/2005.
  • Alcon: C-02-60, Principal Investigator, Anecortave Acetate Risk Reduction Trial for Patients with Non-Neovascular AMD, 03/2004 – 08/2008.
  • Alcon: C-04-59, Principal Investigator, Interval Dose Evaluation of Anecortave Acetate for Those with Neovascular AMD, 01/2005 – 02/2008.
  • Alcon: C-12-006, Principal Investigator, Eylea versus ESBA1008 for the Treatment of Exudative Age-Related Macular Degeneration, 03/2013 - 01/2015.
  • Alcon: C-12-067, Sub-Investigator, Clinical Evaluation to Assess the Safety and Efficacy of Nepafenac 0.3% for Prevention of Macular Edema Following Cataract Surgery in Patients with Diabetic Retinopathy.
  • Alcon: RTH258-C001, Principal Investigator, Intravitreal RTH258 versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration, 03/2015 - 05/2018.
  • Alcon: CRTH258A2301E1, Principal Investigator, Two-arm Extension Study to Collect Efficacy Data on Brolucizumab 6mg in Patients with NVAMD Who Have Completed the RTH258-C001 Study.  12/2017 - 10/2018.
  • Allergan: 206207-008, Sub-Investigator, Posurdex Retinal Vein Occlusion, 01/2005 – 02/2009.
  • Allergan: 206207-010, Sub-Investigator, Posurdex Diabetic Macular Edema, 03/2005 – 03/2013.
  • Allergan: 208397-001, Sub-Investigator, AGN-208397 Retinal Vein Occlusion, 11/2010 -04/2013.
  • Clearside:  CLS1003-301 SAPPHIRE, Sub-Investigator, Suprachoroidal CLS-TA in Conjuction With Intravitreal Aflibercept in Subjects With Retinal Vein Occlusion, 05/2017 -11/2018.
  • DRCR: Intravitreal Triamcinolone Study B, Sub-Investigator, Focal Laser Treatment versus Intravitreal Injection Triamcinolone for Treatment of Diabetic Macular Edema, 06/2005 – 10/2006.
  • DRCR: Protocol T, Sub-Investigator, Aflibercept, Bevacizumab and Ranibizumab for the Treatment of Diabetic Macular Edema, 12/2012 - 08/2015.
  • DRCR:  Protocol V, Sub-Investigator, Aflibercept versus Laser versus Observation for Central Involved DME in Patients With Vision 20/25 or Better, 11/2013 - 04/2019.
  • DRCR: Protocol W, Sub-Investigator, Intravitreal Anti-VEGF Treatment for prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk, 02/2016 - present.
  • DRCR: Protocol AA, Sub-Investigator, Peripheral Diabetic Retinopathy Lesions on Ultrawide-Field Images and Risk of Diabetic Retinopathy Worsening Over Time, 07/2014 - present.
  • DRCR: Protocol AB, Sub-Investigator, Intravitreous Anti-VEGF versus Prompt Vitrectomy for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy, 11/2016 - 08/2019.
  • DRCR: Protocol AC, Sub-Investigator, Intravitreal Aflibercept versus Intravitreal Bevacizumab Plus Deferred Aflibercept for the Treatment of Central Involved Diabetic Macular Edema, 10/2017 - present.
  • DRCR: Protocol TX, Sub-Investigator, Follow-Up Extension Study for Patients Enrolled in DRCR Protocol T, 05/2017 - 8/2019.
  • Eyetech/OSI: EOP1023, Sub-Investigator, Intravitreal Injection of Pegaptanib Sodium for Neovascular AMD, 05/2006 – 07/2008.
  • Eyetech IST: Sub-Investigator, Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease (PRESERVE), Sub-Investigator, Intravitreal Injections of Pegaptanib every 4 weeks compared to every 6 weeks for the treatment of Diabetic Macular Edema, 05/2009 - 10/2011.
  • Eyetech: EOP1024, Sub-Investigator, Intravitreal Injection of Pegaptanib Sodium Administered Every 6 Weeks for 48 Weeks for Subfoveal Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, or Retinal Vein Occlusion to Determine the Adverse Effects on the Corneal Endothelium, 04/2011 – 10/2013.
  • Genaera: 301, Sub-Investigator, Squalamine Lactate IV Infusion for Treatment of Neovascular AMD, 09/2005 – 09/2008.
  • Genentech: FVF4165g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Branch Retinal Vein Occlusion, 02/2008 – 01/2010.
  • Genentech: FVF4166g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion, 02/2008 – 01/2010.
  • Genentech: FVF4168g, Principal Investigator, Intravitreal Injection of Ranibizumab for Diabetic Macular Edema, 08/2007 – 12/2012.
  • Genentech: FVF4295, Sub-Investigator, Evaluation of Ranibizumab on Ease of Procedure and Complications in PDR Requiring Vitrectomy, 09/2007 – 12/2010.
  • Genentech: FVF3426g, Sub-Investigator, Intravitreal Injections of Ranibizumab for Branch Retinal Vein Occlusion and Central Retinal Vein Occlusion for Subjects Who Have Completed a Genentech Sponsored Ranibizumab Study, 02/2009 – 10/2010.
  • Genentech: FVF4579g, Sub-Investigator, Intravitreal Injection of Either 0.5mg or 2.0mg Ranibizumab Administered Monthly or on an as Needed Basis for Subjects with Subfoveal Neovascular Age-Related Macular Degeneration, 06/2009 - 10/2012.
  • Genentech: FVF4967g, Sub-Investigator, Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion, 03/2011 - 01/2013.
  • Genentech:  GX29176, Sub-Investigator, Intravitreal Lampalizumab versus Sham for Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration, 11/2014 - 04/2018.
  • Genentech: GX30191, Sub-Investigator, Open-Label Extension to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to NNVAMD Who Have Completed a Roche-Sponsored Study 10/2106 - 04/2018.
  • Genentech: GR40458, Sub-Investigator, Phase III, Active-Comparator Study of the Efficacy, Safety ad Pharmacokinetics of the Port Delivery System With Ranibizumb in Patients With Neovascular Age-Related Macular Degeneration.  11/2018 - present.
  • Genentech: GR4039, Sub-Investigator, Phase III, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO686761 in Patients With Diabetic Macular Edema, 11/2018 - present.
  • Genentech: GR40306, Sub-Investigator, Phase III, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Neovascular Age-Related Macular Degeneration, 3/2019 - present.
  • Genentech: GR40549, Sub-Investigator, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration, 10/2020 - present.
  • Genentech: GR40550, Sub-Investigator, Phase III, Active-Comparator Study of the Efficacy, Safety and Pharmacokinetics of the Port Deliver System With Ranibizumab in Patients With Diabetic Macular Edema, 10/2019 - present.
  • Genentech: GR41675, Sub-Investigator, Phase III, Study of the Efficacy, Safety and Pharmacokinetics of the Port Deliver System With Ranibizumab in Patients With Diabetic Retinopathy, 09/2020 - present.
  • Eli Lily: B7A-MC-MBCM, Sub-Investigator, Ruboxistaurin Mesylate for Patients with Diabetic Retinopathy, 01/2003– 04/2006.
  • Eli Lily: B7A-MC-MBDV, Sub-Investigator, Open-Label treatment for Patients Completing Study B7A-MC-MBCM, 02/2006-11/2008.
  • Kodiak: KSI-CL-102, Sub-Investigator, Phase II, Double-Masked, Active Comparator-Controlled Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subject With Neovascular Age-Related Macular Degeneration, 09/2019 - present.
  • Lux BioSciences: LX211-11, Sub-Investigator, Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects With Active Non-Infectious Uveitis Involving the Intermediate and/or Posterior Segments of the Eye, 01/2011 - 01/2012.
  • MyLan: MYL-1701P-3001, Sub-Investigator, Active-Controlled, Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Aflibercept in Subjects With Diabetic Macular Edema, 08/2018 - present.
  • NEI:  SCORE2, Sub-Investigator, Intravitreal Bevacizumab versus Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion, 10/2014 - 05/2016.
  • Novartis:  CRTH258AUS04, Principal Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab 6mg q4weeks Compared to Aflibercept 2mg q4weeks in Patients With Neovascular Age-Related Macular Degeneration With Persistent Retinal Fluid, 12/2018 - present.
  • Novartis:  CRTH258B2301, Principal Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema, 09/2018 - present.
  • Novartis: CRTH258C2301, Principal Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion, 07/2019 - present.
  • Novartis: CRTH258C2302, Principal Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion, 07/2019 - present.
  • Novartis: CRTH258B2305, Principal Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema, 10/2019 - present.
  • NGM Bio: NGM621-GA-201, Sub-Investigator, Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration, 10/2020 - present.                         
  • Ophthotech: OPH3000, Sub-Investigator, Intravitreal Injection of Volociximab in Combination With Ranibizumab for Neovascular Age-Related Macular Degeneration, 10/2008 – 12/2009.
  • Ophthotech: OPH1001, Sub-Investigator, Intravitreal Injection of E10030 (Anti-PDGF Peglayted Aptamer) in Combination With Ranibizumab for Neovascular Age-Related Macular Degeneration, 05/2010 – 10/2011.
  • Ophthotech: OPH1003, Sub-Investigator, Intravitreal Injection of Fovista (Anti PDGF-B Pegylated Aptamer) in Combination With Lucentis versus Lucentis Monotherapy for Neovascular Age-Related Macular Degeneration, 09/2013 - 01/2017.
  • Ophthotech: OPH1004, Sub-Investigator, Intravitreal Injection of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Avastin or Eylea Compared to Avastin or Eylea Monotherapy for Neovascular Age-Related Macular Degeneration, 07/2015 - 09/2017.
  • Ophthotech: OPH2003, Sub-Investigator, Intravitreal Administration of Zimura in Subjects With Geographic Atrophy Secondary to NNVAMD, 02/2018 - 11/2018.
  • Ophthea: OPT-302-1002, Sub-Investigator, A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration 12/2017 - 06/2019.
  • Pan Optica: PAN-01-101, Sub-Investigator, Study to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration, 01/2014 - 03/2016.
  • Regeneron: R2176-3-AMD-1417, Sub-Investigator, Multiple-Dose, Regimen Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration, 06/2015 - 04/2017.
  • Regeneron: R910-3-DME-1518, Sub-Investigator, Intravitreal REGN910-3 for Patients With Diabetic Macular Edema, 05/2016 - 10/2017

A Vision to be the Best

As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you.  Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.

Dr. Cooper is currently seeing patients at our Shawnee Mission and Kansas City locations.

Retina Associates, PA logo

Retina Associates, LLC

Retina Associates, LLC is an advanced medical practice devoted to the diagnosis and treatment of retinal, macular, and vitreous diseases. Together, our eye care physicians belong to various prestigious organizations: 

  • American Board of Ophthalmology
  • American Academy of Ophthalmology
  • Association for Research in Vision and Ophthalmology
  • American College of Surgeons
  • American Society of Retina Specialists

Our mission is to help every patient preserve or restore their sight through our advanced treatment options. To discuss your needs with one of our doctors, request an appointment online or call us at (913) 831-7400.

Contact Us

Rate, Review & Explore

Social Accounts Sprite
Google map image of our location in Shawnee Mission, KS

Shawnee Mission Office

9301 W 74th St
Ste 210
Shawnee Mission, KS 66204

Open Today 8:00am - 5:00pm

What is the best time for you?

Add additional time

Tell us a bit about yourself...

(913) 831-7400 Send a message